No Data
Guoyuan Securities 2025 CSI SWS Health Care index investment strategy report: Bullish on innovation and overseas expansion, focusing on upward fundamental segmentation tracks.
The international expansion of the pharmaceutical industry remains an essential path for our country's pharmaceutical companies in the future, and companies with strong product capabilities and channel capabilities are expected to gain an advantage.
Pharmaceutical stocks have become a transitional theme at present, and the performance line may be further valued by the market.
Track the entire lifecycle of the main sector.
Shenzhen Hepalink Pharmaceutical Gets US Distribution License for Anticonvulsant Drug
Hepalink Partners With Yongtai for U.S. Gabapentin Market
HEPALINK (09989.HK) signed a distribution agreement with Yongtai Pharmaceutical.
On January 2, Gelonghui reported that HEPALINK (09989.HK) announced that it had signed a distribution agreement with Zhejiang Yongtai Pharmaceutical Co., Ltd. ("Yongtai Pharmaceutical") on December 31, 2024, under which Yongtai Pharmaceutical granted the company the license to commercialize Gabapentin capsules ("symbol pharmaceutical") throughout the USA. According to the agreement, the company will purchase the symbol pharmaceutical from Yongtai Pharmaceutical at an agreed price and will be responsible for the commercialization of the symbol pharmaceutical in the USA. Aside from the supply price for the symbol pharmaceutical explicitly stated in the agreement, the company is not required to pay any additional amounts to Yongtai Pharmaceutical.
Express News | Shenzhen Hepalink Pharmaceutical - Yongtai Pharmaceutical to Grant Co License to Commercialize Gabapentin Capsules in US
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SZSE:002399) Stocks Pounded By 35% But Not Lagging Market On Growth Or Pricing
No Data
